$VERX

DeStefano David sold $82K of VERX (indirect holdings)

DeStefano David sold 6,460 indirectly-held shares of Vertex, Inc. (VERX) at $12.75 on 2026-05-28.

Original reporting
SEC EDGAR · DeStefano David
Published Jun 1, 2026, 8:17 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 1, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$VERX
Neutral
medium confidence
Mentioned
$VERX
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VERXNeutralLow
01

Why it matters

Traders may treat the disclosure as a minor sentiment datapoint; without accompanying operational news, it should not be weighted like a fundamental update.

02

Market read

Primarily a sentiment/positioning signal; limited incremental information for valuation.

03

What to watch

No 10b5-1 plan is indicated, but the filing alone doesn’t reveal intent, tax timing, or whether other insiders are buying/selling concurrently.

Relevance 6/10Novelty 3/10Timing: After-hours/filing disclosure on 2026-06-01 (SEC Form 4 filed 16:17:29 ET).

Background

The article summarizes an SEC Form 4 insider transaction for Vertex, Inc., showing a director’s open-market sale.

Company-level read

Ticker impact

$VERXNeutralMedium confidence
Context

Vertex director David DeStefano sold 6,460 shares in an open-market transaction totaling $82,365, disclosed via SEC Form 4.

Expected impact

Low near-term impact; any move is likely limited to intraday sentiment around the filing.

Evidence & confidence

The filing is an ownership-change disclosure with no stated new company event (no earnings, trial, deal, or guidance). The sale size is relatively small versus typical market capitalization, and there is no 10b5-1 plan stated.

Market effects

Minimal; this is company-specific insider activity without sector-wide read-through.

None expected beyond US biotech/healthcare sentiment.

None expected.

Counterpoint

The sale may be routine liquidity management (and could be consistent with non-informational motives), so price reaction may be overstated.

Key entities

  • Vertex, Inc.

    Public company whose director reported an open-market sale of shares via SEC Form 4.

  • David DeStefano

    Director who sold 6,460 shares at $12.75/share (total $82,365).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VERXMedAI 8/10

Vertex (VERX) Q2 2026 Earnings Call Transcript

Vertex, Inc. (VERX) reported Q2 2026 revenue of $204 million, up 10.5% year over year and at the high end of guidance. Adjusted EBITDA rose 33% to $51 million, with margin expanding to 25.0%. Subscription revenue grew to $174.8 million and ARR reached $703.4 million. Full-year revenue guidance was narrowed to $825-$830 million and adjusted EBITDA guidance raised to $206-$210 million.

$VERXMedAI 8/10

Vertex Raises Profit Outlook as Cloud Revenue Climbs 18%

Vertex (NASDAQ: VERX) raised its 2026 adjusted EBITDA outlook to $206M-$210M after Q2 revenue rose 10.5% to $204M and cloud revenue grew 17.9% to $101.7M. Full-year revenue guidance was narrowed to $825M-$830M, with 18% cloud growth expected. Q2 adjusted EBITDA rose 32.8% to $51M.

$VERXMedAI 8/10

Vertex Q2 Earnings Call Highlights

Vertex (NASDAQ:VERX) said slower cloud conversion is a timing issue, with customers using mixed cloud and on-prem deployments. Management highlighted strong e-invoicing momentum ahead of France and Germany mandates, expecting e-invoicing to affect ARR in Q3 and more in Q4. Q3 guidance: revenue $208M-$211M, adj. EBITDA $55M-$57M; full-year revenue $825M-$830M and adj. EBITDA $206M-$210M.